Compare · WVE vs XCUR
WVE vs XCUR
Side-by-side comparison of Wave Life Sciences Inc. (WVE) and Exicure Inc. (XCUR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both WVE and XCUR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- WVE is the larger of the two at $560.1M, about 79.2x XCUR ($7.1M).
- Both names hit the wire about 5 times in the past 4 weeks.
- WVE has more recent analyst coverage (24 ratings vs 2 for XCUR).
- Company
- Wave Life Sciences Inc.
- Exicure Inc.
- Price
- -
- -
- Market cap
- $560.1M
- $7.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 5
- 5
- Recent ratings
- 24
- 2
Wave Life Sciences Inc.
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It develops WVE-120101 and WVE-120102, a stereopure therapeutic candidates, which are in Phase 1b/2a clinical trials for the treatment of Huntington's disease (HD); WVE-003, mutant huntingtin SNP3 program for the treatment of HD; WVE-004, C9orf72 program for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-N531, our Exon 53 program for the treatment of Duchenne muscular dystrophy; and ATXN3 program in SCA3. The company has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, and University of Massachusetts. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Exicure Inc.
Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNAÂbased therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha; and AST-005, an SNA targeting TNF for the treatment of mild to moderate psoriasis. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. The company was founded in 2011 and is headquartered in Chicago, Illinois.
Latest WVE
- Wave Life Sciences Highlights WVE-007 (INHBE siRNA) Progress at ObesityWeek® 2026
- Wave Life Sciences to Present at Jefferies Global Healthcare Conference in London
- SEC Form 10-Q filed by Wave Life Sciences Ltd.
- SEC Form 8-K filed by Wave Life Sciences Ltd.
- Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update
- Wave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026
- Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026
- William Blair initiated coverage on Wave Life Sciences
- UBS initiated coverage on Wave Life Sciences with a new price target
- SEC Form DEF 14A filed by Wave Life Sciences Ltd.
Latest XCUR
- Exicure Announces Filing of Notification of Late Filing on Form 12b-25
- SEC Form DEF 14A filed by Exicure Inc.
- Exicure Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Exicure, Inc. Announces Agreement to Sell GPC-100 Program Assets to GPCRT Inc. for KRW 6.5 Billion
- SEC Form PRE 14A filed by Exicure Inc.
- Exicure Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement
- SEC Form 10-Q filed by Exicure Inc.
- Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance
- Large owner Exicure Hitron Inc. acquired $2,804,738 worth of Common (623,275 units at $4.50), increasing direct ownership by 39% to 2,222,224 units (SEC Form 4)